KYKOF (KYKOF) Stock Price & Analysis
KYKOF (KYKOF) fell 10.99% to USD 12.84 as of June 10, 2026 at 05:57 UTC, according to Nexqual real-time market data.
KYKOF last closed at USD 14.43; the session ranged USD 12.84–12.84 on volume of 1 shares. Market capitalization is $6.72B, with a 52-week range of USD 12.42–18 (PNK). Source: Nexqual, June 10, 2026 at 05:57 UTC.
Key Statistics (as of June 10, 2026 at 05:57 UTC)
| Price | USD 12.84 |
|---|---|
| Change | ▼ 10.99% (down) |
| Previous Close | USD 14.43 |
| Open | USD 12.84 |
| Day Range | USD 12.84 – 12.84 |
| 52-Week Range | USD 12.42 – 18 |
| Volume | 1 shares |
| Market Cap | $6.72B |
| Exchange | PNK |
Technical Analysis (KYKOF)
Nexqual's technical model rates KYKOF "SELL" based on 2 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 05:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 14.29) |
| MACD | -0.03 (negative) |
Analyst Ratings (KYKOF)
Wall Street analysts rate KYKOF "None", per Nexqual as of June 10, 2026 at 05:57 UTC.
| Consensus Rating | None |
|---|
Earnings (KYKOF)
| Next Earnings Date | 2026-08-03 |
|---|---|
| Revenue Estimate | $132.91B |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
Financials & Fundamentals (KYKOF)
| Total Revenue | $510.57B |
|---|---|
| Revenue Growth (YoY) | +13.10% |
| Gross Margin | +73.84% |
| Operating Margin | +14.55% |
| Profit Margin | +14.28% |
| ROE | +8.46% |
| Current Ratio | 3.18 |
| Total Cash | $249.52B |
| Total Debt | $0 |
| Free Cash Flow | $36.55B |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
Financial Health Score (KYKOF)
Nexqual rates KYKOF's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:57 UTC.
| Growth | Critical — Revenue -40% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 15% |
| Balance Sheet | Mixed — $249.5B cash, no debt |
| Cash Flow | Solid — FCF $36.5B, 12% margin |
| Efficiency | Mixed — ROE 8%, ROA 6.6% |
Ownership (KYKOF)
| Insider Ownership | +55.00% |
|---|---|
| Institutional Ownership | +19.05% |
| Shares Outstanding | 523.49M |
| Float | 229.42M |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
Leadership (KYKOF)
KYKOF is led by Abdul Hafeez Mullick (age 58), President, CEO & Representative Director, per Nexqual as of June 10, 2026 at 05:57 UTC.
| President, CEO & Representative Director | Abdul Hafeez Mullick (age 58) |
|---|---|
| Chief Financial Officer | Koji Igarashi |
| Executive VP, Chief Scientific Officer & Director | Takeyoshi Yamashita (age 64) |
Major Backers & Investors (KYKOF)
Notable institutional backers of KYKOF include Fidelity, J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF, according to Nexqual as of June 10, 2026 at 05:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.17% |
| J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.18% |
| BlackRock | 0.86% |
Source: Nexqual, June 10, 2026 at 05:57 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CHGCY | Chugai Pharmaceutical Co., Ltd. | USD 22.85 | ▼ 0.91% |
| OPHLY | Ono Pharmaceutical Co., Ltd. | USD 4.56 | ▲ 0.22% |
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 14.96 | ▼ 2.09% |
| SGIOF | Shionogi & Co. Ltd. | USD 17.68 | ▲ 10.5% |
| SGIOY | Shionogi & Co. Ltd. | USD 8.56 | ▼ 2.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:57 UTC. This page is informational and not investment advice.